Clinical evaluation of frequency doubling technology perimetry using the Humphrey Matrix 24-2 threshold strategy

P G D Spry, H M Hussin, J M Sparrow

Aims: To evaluate performance of frequency doubling technology (FDT) perimetry using the Humphrey Matrix 24-2 thresholding program in a hospital eye service (HES) glaucoma clinic.

Methods: A random sample of individuals referred consecutively to the HES for suspected glaucoma were examined with 24-2 threshold FDT in addition to routine clinical tests. The discriminatory power of FDT and standard automated perimetry (SAP) were assessed using glaucomatous optic nerve head appearance as the reference gold standard.

Results: 48 of 62 eligible referred individuals were recruited. Glaucma prevalence was 31%. Median test duration per eye was 5 minutes 16 seconds for FDT and 5 minutes 9 seconds for SAP. There was no significant difference (p = 0.184) between proportions of individuals with reliable test results (FDT 75%, SAP 63%). Using a clinically appropriate binary criterion for abnormal visual field, sensitivity and specificity levels were 100% and 26% respectively for FDT and 80% and 52% for SAP. Both tests had higher negative than positive predictive values with marginal differences between tests. Criterion free receiver operator characteristic analysis revealed minimal discriminatory power differences.

Conclusions: In a HES glaucoma clinic in which new referrals are evaluated, threshold 24-2 FDT testing with the Humphrey Matrix has performance characteristics similar to SAP. These findings suggest threshold testing using the FDT Matrix and SAP is comparable when the 24-2 test pattern is used.

EXTENDED REPORT

Frequency doubling technology (FDT) perimetry was introduced in 1997 and tests contrast sensitivity using spatial frequency doubled stimuli obtained with low spatial frequency stimulus undergoing counterephase flicker at a high temporal frequency. First generation instrumentation utilised 10° targets with suprathreshold screening strategies or thresholding algorithms. Stimulus arrays with up to 19 stimuli within the central 30° of the visual field were available. Reasonable performances have been obtained in evaluations of FDT performance in population screening and hospital glaucoma clinic environments. Given the relatively large size and low density of this FDT stimulus array, changes in the instrument design—specifically increases in the target spatial resolution—may improve visual field defect profile description. Prototype instrumentation using more test locations and a smaller stimulus size has been described, attaining a stimulus resolution increase. With this instrumentation FDT testing using a stimulus pattern equivalent to the Humphrey field analyser 24-2 test pattern resulted in a positive impact on discriminatory power for detection of initial glaucomatous visual field loss. A second generation instrument using similar small FDT stimuli, the Humphrey Matrix, became available for clinical use in 2003. To date, however, scant clinical data are available describing this instrument’s performance.

The aim of this investigation was to evaluate the performance of threshold FDT perimetry using the Humphrey Matrix 24-2 thresholding program in a routine hospital eye service glaucoma clinic environment where referred glaucoma suspects are examined for the first time. Three specific aspects of performance were evaluated by comparison with standard automated perimetry (SAP), (1) the proportion of reliable test results; (2) test duration; and (3) clinical diagnostic capability.
examination, gonioscopy, Goldmann applanation tonometry, dilated posterior segment examination including optic nerve head examination with Volk binocular indirect ophthalmoscopy). The SITA-Fast thresholding strategy was employed in this study as it is the default in the clinic.

The FDT Matrix threshold program 24-2 was carried out either before or after SAP. FDT and SAP were performed in no particular order. A rest interval was provided between tests. Both visual field examinations tested the right eye first.

Stimulus characteristics of the Matrix FDT Program 24-2 test are similar to those previously described for the prototype 24-2 FDT device being 5° square with spatial frequency of 0.5 cycles/° and temporal frequency of 18 Hz. A ZEST thresholding strategy is used with a flat previous probability density function (PDF) and fixed termination criterion.

SAP tests were performed by a pool of clinic staff trained in visual field testing. Subjects wore near spectacle correction if appropriate. For patients habitually wearing bifocal, varifocal, or tinted spectacles, full aperture trial lenses were used.

FDT tests were performed by one investigator (HMH). Individuals wore their distance refractive correction where appropriate. For patients habitually wearing bifocal, varifocal, or tinted spectacles, wide aperture correcting lenses designed for perimetry were used.

The results of the first type of visual field tests (FDT or SAP) were not available to the individual operating the second test type.

Case definition
Case definition was selected to be independent of visual function to permit comparison of FDT with SAP. Individuals were classified as either glaucoma present or absent by identification of optic nerve head (ONH) signs consistent with glaucomatous optic neuropathy (GON) in either eye when examined by a single experienced consultant ophthalmologist (JMS) with a specialist interest in glaucoma. Diagnosis was by patient. The examining ophthalmologist was masked to FDT (JMS) with a specialist interest in glaucoma. Diagnosis was by patient. The examining ophthalmologist was masked to FDT Matrix test results, but had access to SAP results.

Statistical tools
Analysis of proportions was performed by hand using statistical tables. Parametric and non-parametric comparison of paired proportions used SigmaStat 2.0 (Jandel Corporation, San Rafael, CA, USA). ROC analysis of continuous variables versus binary case definition was performed using Intercooled Stata 7.0 (Stata Corporation, College Station, TX, USA).

Figure 1 Bar chart showing distribution of visual field test durations for both FDT (solid bars) and SAP (shaded bars) pooled for both eyes of all recruited patients (n = 48). Median durations were 316 seconds and 309 seconds for FDT and SAP respectively, with hypothesis testing (signed rank test) revealing that the difference was significant (p < 0.001).

Figure 2 Frequency distribution of diagnosis among the sample (n = 48). Individuals with glaucomatous optic neuropathy (n = 15) came from three diagnostic categories, normal tension glaucoma (NTG), primary open angle glaucoma (POAG) and pseudoxfoliative glaucoma (PXF OAG). Suspects (n = 21) comprised individuals with ocular hypertension (OHT) and those with suspicious optic nerve head (ONH) appearance.
RESULTS
Sixty two individuals were randomly selected for participation; 48 (77.4%) were recruited, with the major reason for non-participation being failure to attend the outpatient appointment (n = 9). Other reasons comprised dementia (n = 2), postural problems (n = 2), and deafness (n = 1).

The mean (SD) age of individuals recruited was 67.3 (13.5) years. The male:female ratio was 1:1. The age and sex characteristics of non-participants was similar to participants.

Information about test duration is provided in figure 1. Among the entire sample (both eyes data pooled), the distribution of test durations with FDT was approximately symmetrical, although SAP was negative skewed. The median test duration was 316 seconds for FDT and 309 seconds for SAP. Quantification of test duration spread by standard deviation (SD) revealed that this was greater for SAP than FDT, with SDs of 70 seconds and 24 seconds respectively. The difference in median durations was statistically significant (signed rank test, p <0.001.)

A higher proportion of individuals exhibited reliable tests in both eyes with the Humphrey Matrix (36/48, 75%) than SAP (30/48, 63%), although this difference was not significant at p<0.05 (test of paired proportions, p = 0.184). Of the 12 individuals who were unreliable with FDT, six of these were also unreliable with SAP.

Of the sample of 48 individuals, 15 (31.2%) were found to satisfy the glaucoma case definition (GON in one or both eyes), 21 (43.8%) were identified as suspects that required subsequent monitoring within the HES and 12 (25%) were normal. Further diagnostic information is provided in figure 2.

The results of analysis based on collapsing visual field data into a binary outcome of abnormal visual fields are given in table 1. Overall, it can be seen that both visual field tests exhibited higher sensitivity than specificity, with FDT exhibiting higher sensitivity and SAP higher specificity. Predictive values were consistent with these sensitivity and specificity estimates, as evidenced by negative predictive values exceeding positive predictive values for both tests. Overall, FDT had marginally higher predictive values than SAP.

In order to gain some insight in the performance of FDT at differing levels of visual loss on standard perimetry, the proportion of individuals with abnormal FDT at varying degrees of SAP abnormality was investigated (see fig 3). The proportion of individuals having abnormal FDT results increased with increasing SAP defect severity, quantified by MD.

It can be seen from criterion free analysis based on continuous variables (see fig 4) that performance of both test types for each variable substantially exceeded chance. The SAP area under ROC demonstrated minimally higher discriminatory performance than FDT.

DISCUSSION
This study provides evidence that performance of threshold 24-2 FDT perimetry is comparable to SAP 24-2 in the key areas of proportion of reliable test results obtained, test duration, and diagnostic accuracy. The pragmatic experimental design allows findings to be generalised to hospital eye service (HES) clinics used for initial assessment of patients with suspected glaucoma.

In terms of reliability, the proportion of reliable test results by FDT perimetry (75%) was similar to that described for SAP in other reports of perimetrically naive patients. More patients were found to be reliable with FDT than SAP (62.5%), although this difference was not significant.

The sample comprised a variety of visual field defect magnitudes. Average test time for FDT was just over 5 minutes. Although this was statistically significantly greater than SAP, it is reasonable to suggest that the
difference of 7 seconds is not clinically important. This test duration should be contrasted with reports from both threshold strategies of the first generation FDT device, such as program C20 (seventeen 10° test targets within central 20°) and also the prototype 24-2 FDT device (“Quadrasvision”). Reports from first generation C20 FDT testing in glaucoma patient groups of varying size and composition described average test times between 4 minutes and 6 minutes,10-14 therefore, similar to our data with the threshold program 24-2 on the Matrix device, despite lower spatial stimulus resolution. Data collected with the Quadrasvision prototype 24-2 FDT device yielded an average test time in 23 patients with early glaucomatous visual field loss of approximately 12 minutes.7 The differences between these devices and the Matrix FDT may be attributed to use of a thresholding strategy whereby both first generation FDT perimeter and the prototype 24-2 device employ a modified binary search (MOBS) thresholding strategy15 unlike the matrix, which uses a Bayesian strategy, specifically ZEST,16 with a fixed number of presentations at each test location and a flat previous probability density function (PDF). Both simulated and empirical laboratory FDT data show that use of ZEST, albeit with a dynamic termination criterion, can produce results of similar accuracy and reliability in approximately 50% of test time.22,23 Furthermore, fixed termination criterion use does not impact on detection of threshold inaccuracies,22 although the effect of a flat PDF remains unknown.

In terms of diagnostic accuracy FDT and SAP produced broadly similar results, yielding considerably higher sensitivities than specificity. Obviously, alternative outcome criteria could have been applied: this particular criterion being selected because it was considered typical of that applied by clinic staff. The impact of this criterion demonstrated that it was relatively liberal (that is, higher sensitivity). Criterion free analysis obtained minimal differences in discriminatory power between the two test types. It is possible, however, that this may have differed if the SITA-Standard thresholding algorithm had been used for SAP, although this would have increased duration. It is also important to consider that a potential source of differential information bias existed in favour of SAP because the examining ophthalmologist had access to the results of this test.

Although considerable published data exist on performance of the first generation FDT perimeter, to our knowledge there are no reports on clinical performance of the Humphrey Matrix in the literature. Many research groups have reported on the clinical performance of the first generation FDT screening (suprathreshold) tests with the broad consensus of high levels of discriminatory power for identification of glaucomatous visual field loss, which appears to be associated with the degree of achronic field loss.11,12 Specifically, some investigators have described reasonable discriminatory power in population screening studies for the presence of any abnormality likely to cause a visual field defect.1 A glaucoma population screening study obtained optimal levels of FDT discrimination of 92% sensitivity and 93% specificity. Similarly, other studies report good discriminatory performance with the same screening tests in hospital glaucoma clinic environments,10 although these studies terms of limited generalisability owing to differing selection criteria. Fewer data are available on threshold strategies of this instrument, with a single available comparative report of suprathreshold and full threshold strategies suggesting that threshold FDT perimetry improved discriminatory power compared with suprathreshold screening tests.3 Specifically, for threshold 24-2 FDT, a cross sectional study performed with the prototype device found a greater proportion of abnormal test locations with threshold 24-2 than threshold C20, both in individuals with early glaucoma and high risk glaucoma suspects, implying modest sensitivity improvements. The shape of visual field defects was also found to be better characterised.7

In the context of population screening, the aim of an initial or primary screening round is to identify as many individuals with the disease as possible while taking into account the costs and benefits of disease detection, capability of the continuing care system, and disease prevalence. In the context of a low prevalence disease such as chronic open angle glaucoma where the course of untreated disease is generally slow and repeated testing is feasible, it can be argued that selection of primary population screening tests and abnormality criteria should compromise sensitivity to achieve optimal specificity and positive predictive values. The purpose of this is to avoid excessive demands (high false positive rates) upon referral centres. However, for secondary screening of enriched prevalence populations, such as those failing a primary screen, the priority becomes identification of all cases of disease within the re-screened group, therefore demanding optimal sensitivity and negative predictive value—that is, compromised specificity. With this approach in mind, the performance of FDT in this study’s enriched glaucoma prevalence population suggests suitability for use in a secondary screening environment, such as initial assessment of glaucoma suspects within the HES, or referral refinement schemes.19 The estimations of negative predictive values and positive predictive values suggest that FDT is at least as valuable in this capacity as SAP.

Data obtained in this study suggest that threshold 24-2 FDT has desirable characteristics for initial glaucoma detection in HES environments. However, at the present time care should be taken not to interpret this as suggesting that this technology may have a role in monitoring individuals for progressive glaucoma and therefore longitudinal data upon sensitivity to change are awaited with interest.

**Authors’ affiliations**

P G D Spry, H M Hussin, J M Sparrow, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK

Commercial relationships: PGDS has received research funds from Welch-Allyn, Skaneateles, NY, USA. HMM and JMS have no commercial relationships.

**REFERENCES**


